Engineering HEK293T cell lines to express nuclease for DNA clearance in lentiviral vector production
Author(s)
Type
Conference Paper
Abstract
To improve the purity of lentiviral vectors (LVV) for cell and gene therapy applications manufacturers’ currently remove residual DNA using a DNase treatment step with endonucleases such as Benzonase. This is a prohibitively expensive but necessary step in the manufacturing process as regulators require concentrations of less than 10 ng/dose at sizes less than 200 base pairs in the final product. As an alternative we have engineered serum-free adapted HEK293T cells to express nuclease enzymes to remove DNA impurities from LVV supernatant. Three nuclease expression cassettes were designed by fusing the N-terminus of the Staphylococcus aureus nuclease B (nucB) open reading frame to: the native S. aureus nuclease signal peptide, the mammalian murine Igκ chain leader sequence, and a virus-encoded transport protein. The Tet repressor system was selected to regulate expression of nucB to reduce cell cytotoxicity and any negative effects on lentivirus production from potential intracellular nuclease expression and constitutive nuclease secretion. All three nuclease expression cassettes demonstrated levels of activity equivalent to or better than Benzonase at 250 units in growth medium harvested from engineered cell lines 24 hours post tetracycline induction. When treating 1.5 µg 1 kb DNA ladder (500 base pairs to 10 kilobase pairs), 2-hour incubations at 37ºC with 10 µL of growth media reduced DNA ladder to non-visible sizes on 1% agarose gel. To verify that a nuclease secreting cell line can support LVV production, a LVV encoding for green fluorescent protein was prepared by transient polyethylenimine transfection. Nuclease activity was demonstrated in fractions collected during LVV production and had no measurable effect on infectious titre of the clarified supernatant when transducing both HEK293T and AGF-T cells under serum-free conditions. This provides a holistic approach to remove residual DNA early in the process stream and improve the purity of the final product, whilst avoiding the addition of exogenous nuclease and its associated costs at scale. This may also potentially reduce any deficiencies of downstream processing attributed to the viscosity of residual DNA.
Date Issued
2021-08-22
Date Acceptance
2021-06-18
Citation
2021
Publisher
ACS
Copyright Statement
© 2021 The Author(s). Available under a Creative Commons Attribution-NonCommercial-NoDerivs CC BY 4.0
Source
American Chemistry Society Fall (ACS Fall 2021)
Subjects
Bioprocessing
Cell line engineering
Cell Therapy
Gene Therapy
Lentiviral vector
Nuclease
Serum-free
Start Date
2021-08-22
Finish Date
2021-08-26
Coverage Spatial
Atlanta Georgia, USA